Phase 1 Single Ascending and Multiple Ascending Dose Study with LCA-0321
Latest Information Update: 02 Apr 2026
At a glance
- Drugs LCA 0321 (Primary)
- Indications Graves' disease
- Focus Adverse reactions; First in man
- Sponsors Lycia Therapeutics
Most Recent Events
- 19 Mar 2026 New trial record